Fig. 2

Consort flow diagram of the progress through the RCT and the open-label phases of a randomized, double-blind, and placebo-controlled clinical trial of the OEA supplementation. This diagram shows the flow of participants in each arm of the study. Twenty-six participants were randomized to each of the placebo and the OEA groups. One participant in the placebo group was lost to follow-up during the RCT. One placebo participant was non-compliant by the end of the RCT, and 1 withdrew consent in the OEA group.